Eos Energy Enterprises Inc vs Cassava Sciences Inc — how do they compare? Eos Energy Enterprises Inc trades at $3.97 (market cap $1.55B), while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: Eos Energy Enterprises Inc is far larger — about 29.2× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| EOSE | FLNA | |
|---|---|---|
Market Cap | $1.55B | $53.14M |
Sector | Energy | Health |
52-Week High | $19.19 | $4.64 |
52-Week Low | $4.29 | $1.09 |
Enterprise Value | $1.79B | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.99, down 6.99% on the day, reflecting a challenging fundamental picture with significant losses. The company reported a net loss of $969.65M on $114.20M revenue for 2025, though recent Q1 2026 results showed a surprise EPS beat. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while the stock is consolidating near a key $4 support level. Recent news highlights accelerating commercial execution, including a major project selection for the Golden Dome initiative and preliminary Q2 2026 results pointing to record quarterly revenue and backlog.
The outlook presents a high-risk, high-reward scenario. Significant revenue acceleration and project backlog growth offer potential upside, supported by a consensus analyst price target of $9.00 (125% upside). However, deep negative margins, substantial cash burn, and a highly leveraged balance sheet with 91.87% debt-to-asset ratio pose severe financial risks. Investment success hinges on the company's ability to achieve manufacturing scale and path to profitability in the competitive energy storage market.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →